Unicycive Therapeutics Inc
NASDAQ:UNCY
Unicycive Therapeutics Inc
NASDAQ:UNCY
Price:
7.43
USD
5.84%
Market Closed
Market Cap:
$187.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Unicycive Therapeutics Inc
NASDAQ:UNCY
|
US |
|
X
|
XL Holdings Bhd
KLSE:XL
|
MY |
|
C
|
Cyberjaya Education Group Bhd
KLSE:CYBERE
|
MY |
|
Vizio Holding Corp
NYSE:VZIO
|
US |
|
G
|
Guangdong Taienkang Pharmaceutical Co Ltd
SZSE:301263
|
CN |
|
P
|
Pricer AB
STO:PRIC B
|
SE |
Income Statement
Earnings Waterfall
Unicycive Therapeutics Inc
Unicycive Therapeutics Inc
Income Statement
Unicycive Therapeutics Inc
Unicycive Therapeutics Inc
Currency: USD
| Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
1
N/A
|
2
+72%
|
2
N/A
|
1
-58%
|
1
-1%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(7)
|
(9)
|
(12)
|
(15)
|
(16)
|
(19)
|
(20)
|
(21)
|
(20)
|
(21)
|
(26)
|
(29)
|
(29)
|
(32)
|
(31)
|
(30)
|
|
| Selling, General & Administrative |
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(3)
|
(4)
|
(6)
|
(6)
|
(7)
|
(7)
|
(7)
|
(8)
|
(9)
|
(9)
|
(10)
|
(10)
|
(12)
|
(16)
|
(18)
|
|
| Research & Development |
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(5)
|
(6)
|
(8)
|
(9)
|
(10)
|
(12)
|
(14)
|
(14)
|
(13)
|
(13)
|
(17)
|
(19)
|
(19)
|
(20)
|
(15)
|
(12)
|
|
| Operating Income |
(2)
N/A
|
(2)
-8%
|
(2)
0%
|
(2)
-20%
|
(3)
-18%
|
(7)
-143%
|
(9)
-29%
|
(12)
-31%
|
(15)
-24%
|
(15)
-6%
|
(18)
-17%
|
(19)
-4%
|
(19)
-4%
|
(20)
-2%
|
(21)
-5%
|
(26)
-24%
|
(29)
-12%
|
(29)
-1%
|
(32)
-10%
|
(31)
+4%
|
(30)
+1%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(10)
|
(10)
|
(9)
|
(10)
|
(12)
|
5
|
5
|
(6)
|
14
|
(2)
|
|
| Pre-Tax Income |
(2)
N/A
|
(2)
-7%
|
(2)
-9%
|
(3)
-27%
|
(4)
-26%
|
(8)
-124%
|
(10)
-23%
|
(13)
-26%
|
(15)
-20%
|
(15)
-2%
|
(18)
-17%
|
(29)
-61%
|
(29)
-1%
|
(28)
+4%
|
(31)
-9%
|
(37)
-21%
|
(23)
+37%
|
(23)
+1%
|
(37)
-60%
|
(15)
+59%
|
(31)
-107%
|
|
| Net Income | ||||||||||||||||||||||
| Income from Continuing Operations |
(2)
|
(2)
|
(2)
|
(3)
|
(4)
|
(8)
|
(10)
|
(13)
|
(15)
|
(15)
|
(18)
|
(29)
|
(29)
|
(28)
|
(31)
|
(37)
|
(23)
|
(23)
|
(37)
|
(15)
|
(31)
|
|
| Net Income (Common) |
(2)
N/A
|
(2)
-7%
|
(2)
-9%
|
(3)
-27%
|
(4)
-26%
|
(8)
-124%
|
(10)
-23%
|
(13)
-26%
|
(15)
-20%
|
(15)
-2%
|
(18)
-17%
|
(29)
-62%
|
(30)
-3%
|
(29)
+4%
|
(31)
-9%
|
(32)
-2%
|
(24)
+23%
|
(24)
+1%
|
(38)
-57%
|
(22)
+42%
|
(32)
-43%
|
|
| EPS (Diluted) |
-1.33
N/A
|
-1.43
-8%
|
-1.55
-8%
|
-1.98
-28%
|
-2.51
-27%
|
-5.74
-129%
|
-6.68
-16%
|
-8.39
-26%
|
-10.06
-20%
|
-10.28
-2%
|
-11.99
-17%
|
-19.23
-60%
|
-19.75
-3%
|
-8.87
+55%
|
-12.8
-44%
|
-8.58
+33%
|
-2.59
+70%
|
-2.7
-4%
|
-5.65
-109%
|
-1.78
+68%
|
-2.56
-44%
|
|
Switch to:
Switch to:
See Also
Discover More
